Jewim Pharmaceutical (Shandong) Co., Ltd

Primary objective: Based on the relevant regulations for bioequivalence studies, a fluticasone propionate suspension for nebulized inhalation (2 ml, 0.5 mg) manufactured by GlaxoSmithKline Australia Pty Ltd. was selected as the reference preparation. A fasting bioequivalence study was conducted on the test preparation, fluticasone propionate suspension for nebulized inhalation (2 ml, 0.5 mg), manufactured and provided by Shandong Jingwei Pharmaceutical Co., Ltd. The pharmacokinetic characteristics of the test preparation and the reference preparation were compared, and the bioequivalence of the two preparations under fasting conditions was evaluated. Secondary objective: To observe the safety of oral inhalation of the test preparation, fluticasone propionate suspension for nebulized inhalation (2 ml, 0.5 mg), and the reference preparation, fluticasone propionate suspension for nebulized inhalation (2 ml, 0.5 mg), in healthy volunteers.

The main purpose of this study was to conduct a postprandial bioequivalence study on the entacapone bidopa tablets (II) (trade name: Stalevo®; strength: levodopa 100 mg, carbidopa 25 mg, and entacapone 200 mg) produced and provided by Shandong Jingwei Pharmaceutical Co., Ltd. in accordance with the relevant bioequivalence test regulations. The study aimed to compare the absorption rate and extent of the drug in the test preparation with those of the reference preparation to determine whether they were within an acceptable range, and to evaluate the bioequivalence of the two preparations under postprandial administration conditions. Secondary study objective: To observe the safety of oral administration of the test preparation Entacapone Bidopa Tablets (II) (specifications: levodopa 100 mg, carbidopa 25 mg and entacapone 200 mg) and the reference preparation Entacapone Bidopa Tablets (II) (trade name: Stalevo®; specifications: levodopa 100 mg, carbidopa 25 mg and entacapone 200 mg) in healthy subjects.

Main study objectives To evaluate the pharmacokinetic characteristics and bioequivalence of the test formulation of melogabalin besylate tablets (specification: 15 mg, applicant: Shandong Jingwei Pharmaceutical Co., Ltd.) and the reference formulation (trade name: Tarlige®, specification: 15 mg, licensee: Daiichi Sankyo Co., Ltd.) after a single oral dose in healthy Chinese adult subjects under fasting and postprandial conditions. Secondary study objectives To study the safety of the test formulation of melogabalin besylate tablets (specification: 15 mg) and the reference formulation (trade name: Tarlige®, specification: 15 mg) in healthy Chinese adult subjects.